tegoprazan

a novel Potassium-competitive acid blocker

Also Known As:

(S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo(d)imidazole-6-carboxamide; 1H-Benzimidazole-5-carboxamide, 7-(((4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl)oxy)-N,N,2-trimethyl-; 7-(((4S)-5,7-Difluoro-3,4-dihydro-2H-chromen-4-yl)oxy)-N,N,2-trimethyl-1H-benzimidazole-5-carboxamide

Networked: 20 relevant articles (7 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Song, Geun Seog: 4 articles (01/2021 - 10/2019)
2.	Baik, Gwang Ho: 2 articles (01/2022 - 01/2020)
3.	Chun, Hoon Jai: 2 articles (01/2022 - 01/2021)
4.	Jung, Hye-Kyung: 2 articles (01/2022 - 01/2020)
5.	Kim, Byung-Wook: 2 articles (01/2022 - 01/2020)
6.	Kim, Kyoung Oh: 2 articles (01/2022 - 01/2020)
7.	Kim, Sang Gyun: 2 articles (01/2022 - 01/2021)
8.	Ko, Kwang Hyun: 2 articles (01/2022 - 01/2021)
9.	Lee, Yong Chan: 2 articles (01/2022 - 01/2021)
10.	Lim, Yun Jeong: 2 articles (01/2022 - 01/2020)

Related Diseases

1.	Infections 10/01/2019 - "To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of tegoprazan METHODS: A phase I, randomised, double-blind and placebo-controlled clinical trial was conducted in 56 healthy male subjects without Helicobacter pylori infection. " 10/01/2022 - "7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence." 06/01/2023 - "Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study." 10/01/2022 - "pylori infection is treated with tegoprazan-based triple therapy in regions with high clarithromycin resistance." 10/01/2022 - "pylori infection with tegoprazan-based triple therapy (50 mg tegoprazan + 1000 mg amoxicillin + 500 mg clarithromycin twice daily for 1 or 2 weeks). "
2.	Heartburn (Pyrosis) 01/30/2023 - "The percentage of nighttime heartburn-free days was higher in the tegoprazan group but the difference was insignificant (57.8% vs 43.1%, P = 0.107). " 01/01/2021 - "The complete resolution rates of heartburn and proportions of heartburn-free days (as other efficacy outcomes) were significantly higher in both tegoprazan groups than in the placebo group (P < 0.05 for all). " 01/30/2023 - "Tegoprazan may induce faster relief of nighttime heartburn symptoms and may improve sleep disorders associated with nighttime heartburn. " 01/30/2023 - "This study aims to evaluate the efficacy of tegoprazan compared with esomeprazole in relieving nighttime heartburn and sleep disturbances. " 01/30/2023 - "Time to the first nighttime heartburn-free interval was shorter with tegoprazan than with esomeprazole but the difference was not statistically significant (1.5 days vs 3 days, P = 0.151). "
3.	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 04/28/2023 - "Tegoprazan as a New Remedy for Gastrointestinal Diseases in Comparison with its Therapeutic Predecessors: A Mini-Review." 04/28/2023 - "A number of studies have compared the effectiveness as well as the safety profile of tegoprazan to PPIs and other P-CABs for the treatment of gastrointestinal diseases. " 04/28/2023 - "The findings of this study revealed that tegoprazan is safe and well-tolerated and can be used to treat a group of gastrointestinal diseases, including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), and H. " 01/01/2019 - "Tegoprazan, a novel potassium-competitive acid blocker (P-CAB), is a next-generation therapeutics developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and peptic ulcers. "
4.	Colitis 01/01/2022 - "The present study revealed that tegoprazan, a potassium-competitive acid blocker, significantly improved colitis in mice and enhanced the intestinal epithelial barrier function. " 01/01/2022 - "Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function."
5.	Laryngopharyngeal Reflux 09/22/2023 - "Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study." 09/22/2023 - "We performed a preliminary feasibility study to evaluate whether tegoprazan could control symptoms more effectively than a placebo in patients with laryngopharyngeal reflux disease (LPRD). "

Related Drugs and Biologics

1.	Potassium
2.	Acids
3.	Esomeprazole (Nexium)
4.	Bismuth
5.	Bicarbonates (Hydrogen Carbonate)
6.	Lansoprazole (Prevacid)
7.	Proton Pump Inhibitors
8.	Sodium Bicarbonate (Baking Soda)
9.	Rabeprazole (Aciphex)
10.	Clarithromycin (Biaxin)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration